Nextcea

500 West Cummings Park, Suite 4550
Woburn, MA 01801, USA
Phone: +1 781 457 4010
Fax: +1 617 812 2684
www.nextcea.com
e-mail: inform@nextcea.com

# Drug-Induced Phospholipidosis GLP/non-GLP Assessments: Sample Requirements

Drug induced phospholipidosis (DIPL) is a phospholipid storage disorder characterized by an excessive accumulation of multi-lamellar bodies (myeloid bodies) in cells and tissues. The patented biomarker di-docosahexaenoyl (22:6)-BMP (di-22:6-BMP) is a lysosomal phospholipid that is increased in the tissues of animals and humans with DIPL. Nextcea uses validated high sensitivity LC-MS/MS methods to measure the absolute concentrations of di-22:6-BMP in plasma/serum, urine, and tissue samples.

## Non-clinical Samples

| Sample Type | Collection | Sample Volumes/Weight | Storage/Shipping of Specimens |
|---|---|---|---|
| Serum/Plasma | Plasma: Choice of anticoagulant such as sodium heparin or lithium heparin | ~ 300 µL | ▪ Store in -80°C freezer.<br>▪ Ship frozen on dry ice |
| Urine | Non-clinical: Overnight urine collection in cooling cage pan | ~ 300 µL | ▪ Store in -80°C freezer.<br>▪ Ship frozen on dry ice |
| Tissues (lung, liver, kidney, heart etc.) | Snap-frozen | ~ 300 mg | ▪ Store in -80°C freezer.<br>▪ Ship frozen on dry ice |

## Clinical Samples

| Sample Type | Collection | Sample Volumes | Storage/Shipping of Specimens |
|---|---|---|---|
| Serum/Plasma | Plasma: Choice of anticoagulant such as sodium heparin or lithium heparin | ~ 300 µL | ▪ Store in -80°C freezer.<br>▪ Ship frozen on dry ice |
| Urine | Preferred mid-stream urine sample. | ~ 1 mL | ▪ Store in -80°C freezer.<br>▪ Ship frozen on dry ice |

* Serum, plasma, and urine samples may be stored up to 1 year at -80 °C before use.

Hsieh F., Tengstrand E. Detecting Phospholipidosis and Diagnosing Lysosomal Storage Disorders. US Patent 8,313,949, Japanese Patent 5,702,363, and European Patent EP2419742.

Liu N., Tengstrand E., Chourb L., and Hsieh F. Di-22:6-bis(monoacylglycerol)phosphate: a clinical biomarker of drug-induced phospholipidosis for drug development and safety assessment. Toxicology and Applied Pharmacology 2014;279(3):467-476.

Tengstrand E., Miwa G., and Hsieh F. Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug induced toxicities. Expert Opinion in Drug Metabolism and Toxicology 2010; 6(5):555-570.

Tengstrand-Baronas E., Lee J.W., Alden C., and Hsieh F. Biomarkers to monitor drug-induced phospholipidosis. Toxicology and Applied Pharmacology 2007;218:72-78.

Thompson, K.L., Haskins, K., Rosenzweig, B.A., Stewart, S., Zhang, J., Peters, D., Knapton, A., Rouse, R., Mans, D., and Colatsky T. Comparison of the diagnostic accuracy of di-22:6-bis(monoacylglycerol)phosphate and other urinary phospholipids for drug-induced phospholipidosis or tissue injury in the rat. International Journal of Toxicology 2012;31(1): 14-24.

Thompson, K.L., Zhang, J., Stewart, S., Rosenzweig, B.S., Shea, K., Mans, D., and Colatsky, T. Comparison of urinary and serum levels of di-22:6-bis(monoacylglycerol)phosphate as noninvasive biomarkers of phospholipidosis in rats. Toxicology Letters. 2012;213(2), 285-91.